NCT04087473

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Plasma Molecular Profiling in ALK Inhibitor Resistant Non-Small Cell Lung Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: National Cancer Centre, Singapore · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The investigators plan to understand a comprehensive molecular profiling via the plasma, with the primary aim of using this form on analysis to guide subsequent treatment selection. This study will provide a better understanding of ALK resistance in the treatment of Asian lung cancers and allow for improved clinical outcomes by 'matching' the secondary mutations to an ALK inhibitor which would allow for the greatest coverage ultimately leading to lasting duration of response.

Conditions

• Non-small Cell Lung Cancer
• ALK-Positive Lung Cancer

Timeline

• Start date: 2019-08-23
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2019-09-12
• Last updated: 2025-06-12

Locations

5 sites across 4 countries: Hong Kong, Malaysia, Singapore, South Korea